Business Wire

Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace

16.12.2025 03:00:00 CET | Business Wire | Press Release

Share

Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia.

This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators.

NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing for medical containers, including vials, ampoules, pre-filled syringes, and cartridges. Demand for these containers has surged, driven by the global expansion of biopharmaceuticals. Specifically, markets for GLP-1 formulations (for diabetes and obesity treatments) are growing at approximately 33% annually*2, with rising demand across North America, Europe, and emerging regions like India and China. By establishing this high-volume, low-emission manufacturing platform, NEG aims to support these rapidly growing global needs.

Comment from Masamori Wada, Vice President:

“Launching the world’s first mass production line for pharmaceutical glass tubing using an all-electric furnace is a major milestone. We see this as a concrete step toward carbon-neutral pharmaceutical supply chains, enabling customers to choose products that are both high-grade and environmentally responsible.”

A shift in how pharmaceutical glass is made traditional glass melting uses fossil fuels, generating large amounts of CO2 and waste heat. NEG’s all-electric furnace uses its proprietary NEG Electric Melting TechnologyTM, which applies electricity to submerged electrodes to heat glass directly. This achieves high energy efficiency, eliminates combustion gas emissions, and dramatically cuts environmental impact while maintaining the high quality required for pharmaceutical glass.

*1 Estimated on the assumption that production is carried out at Nippon Electric Glass (Malaysia) Sdn. Bhd. using an all-electric melting furnace with renewable energy.
*2 Prophecy Market Insights

View source version on businesswire.com: https://www.businesswire.com/news/home/20251215772086/en/

Contacts

Company
Nippon Electric Glass Co., Ltd. (NEG)
https://www.neg.co.jp/en/ -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.neg.co.jp%
2Fen%2F&esheet=54371242&newsitemid=20251215772086&lan=en-US&anchor=https%3A%2F%2
Fwww.neg.co.jp%2Fen%2F&index=1&md5=d2a46dd6e00b10dd3674e7a7421405b1

Product Inquiry
https://form.neg.co.jp/webapp/form/26624_aknb_8/index.do?term_slug=43&post_slug=
119 -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fform.neg.co.jp
%2Fwebapp%2Fform%2F26624_aknb_8%2Findex.do%3Fterm_slug%3D43%26post_slug%3D119&es
heet=54371242&newsitemid=20251215772086&lan=en-US&anchor=https%3A%2F%2Fform.neg.
co.jp%2Fwebapp%2Fform%2F26624_aknb_8%2Findex.do%3Fterm_slug%3D43%26amp%3Bpost_sl
ug%3D119&index=2&md5=21f57dc576b1444d0faa0ddc500ffbc7

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Meiji Seika Pharma’s Morcamilast (ME3183) was Granted Orphan Medicinal Product Designation by the European Commission for Palmoplantar Pustulosis3.3.2026 02:00:00 CET | Press Release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that morcamilast (proposed international nonproprietary name; development code: ME3183), a selective phosphodiesterase-4 (PDE4) inhibitor, has been granted orphan medicinal product designation by the European Commission (EC) for the treatment of palmoplantar pustulosis (PPP). Palmoplantar pustulosis is a chronic inflammatory disease characterized by the development of multiple sterile pustules on the palms and soles. Patients often experience pain and pruritus of the skin, and the condition can be accompanied by nail involvement and joint pain. Because lesions on the palms are visible to others and lesions on the soles can cause pain while walking, daily functioning can be significantly restricted, leading in a substantial reduction in quality of life. PPP has a pathophysiology distinct from psoriasis and pustular psoriasis, and treatment can be challenging, unde

Yubico Establishes Singapore as Third Global Headquarters Accelerating Asia Pacific Growth3.3.2026 01:00:00 CET | Press Release

Yubico (NASDAQ STOCKHOLM: YUBICO), a cybersecurity company, inventor of FIDO passkeys and creator of the YubiKey, the most secure passkey, today announced the opening of its third global headquarters in Singapore. This announcement reinforces Yubico’s long-term commitment to the Asia Pacific region and builds on its role in advancing open authentication standards, while shaping a safer digital world for all. The new office complements Yubico’s existing global headquarters in Stockholm, Sweden and Santa Clara, USA, reflecting its strategy to serve a growing international user base by helping customers deploy YubiKeys at scale to adapt to a rapidly evolving cybersecurity landscape. “As the digital economy grows, there’s a decisive shift across Asia Pacific, where organizations are moving beyond legacy multi-factor authentication to meet rigorous new national regulations for identity protection,” said Jerrod Chong, Acting Chief Executive Officer at Yubico, a Singaporean. “The expansion of

IFF Completed the Divestiture of Soy Crush, Concentrates and Lecithin Businesses2.3.2026 22:15:00 CET | Press Release

IFF (NYSE: IFF) today announced that it has successfully completed the previously announced divestiture of its soy crush, concentrates and lecithin businesses to Bunge. This transaction does not include IFF’s soy isolates business. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent, food ingredients, health and biosciences, we’re innovating for the future. Every day, we deliver groundbreaking, sustainable solutions that elevate products people love — advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20260302231096/en/

Verimatrix ReAccess Earns Gold 2026 Merit Award for Telecom & Wireless2.3.2026 17:50:00 CET | Press Release

Regulatory News: Verimatrix (Euronext Paris: VMX), a leading provider of security solutions for a safer connected world, today announced that its Verimatrix ReAccess solution was honored with a gold 2026 Merit Award for Telecom & Wireless. The industry accolade recognizes the company’s next-generation content security solution that modernizes legacy Conditional Access Systems (CAS) across DVB, IPTV and OTT networks without requiring costly hardware replacements or field service interventions. Judged by industry executives, media professionals and technology consultants, the Merit Awards evaluate submissions from across the telecommunications landscape. Verimatrix ReAccess enables secure, over-the-air (OTA) software updates to deployed set-top boxes (STBs), delivering operator cost savings, reduced operational complexity, and ongoing protection against piracy. It also empowers operators to continuously strengthen content security, eliminating the need for costly hardware replacements. U

Textron Aviation Launches Donation Campaign to Support 2026 Special Olympics Airlift; Continues Nationwide Call for Volunteer Doves2.3.2026 17:00:00 CET | Press Release

Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced the launch of a donation campaign benefitting Special Olympics in support of the 2026 Special Olympics Airlift, a nationwide effort that brings athletes and coaches to the Special Olympics USA Games through the generosity of volunteer pilots, aircraft owners and operators known as Doves. Financial contributions go directly to the Special Olympics, a 501(c)(3) charitable organization. New for the 2026 event, the donation campaign serves a vital role in ensuring each delegation has what it needs for a smooth and welcoming travel experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260302196418/en/ Textron Aviation launches donation campaign to support 2026 Special Olympics Airlift; continues nationwide call for volunteer Doves (Photo credit: Textron Aviation). “This campaign reflects the spirit of unity and generosity that defines the Special Olym

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye